December 4, 2009 (FinancialWire) — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) said that Robert L. Zerbe, M.D., has joined the company’s board and will be an active member of the company’s compensation committee.

Zerbe currently serves as chief executive officer and president at QuatRx Pharmaceuticals, a private biopharmaceutical company he co-founded in 2000. Prior to QuatRx, he served as senior vice president of Worldwide Clinical Research and Development at Parke-Davis, during which time he oversaw the development programs for Lipitor, Neurontin, and other products.

San Diego-based Optimer Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products to treat serious infections and address unmet medical needs.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279). The most recently issued reports and/or recorded webcasts include Cascade Corp. (NYSE: CASC), Anadarko Petroleum Corp. (NYSE: APC), Baytex Energy Trust (NYSE: BTE) (TSX: BTE), H & Q Healthcare Investors (NYSE: HQH), H & Q Life Science Investors (NYSE: HQL), PIMCO (NYSE: PYN) (NYSE: PMX) (NYSE: PZC), PIMCO Global StocksPLUS & Income Fund (NYSE: PGP), Taiwan Greater China Fund (NYSE: TFC) and Wolseley PLC (OTC: WOSCF) (London Stock Exchange: WOS).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.